Focused On-demand Library for Small ribosomal subunit protein bS1m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y2Q9

UPID:

RT28_HUMAN

Alternative names:

28S ribosomal protein S28, mitochondrial; 28S ribosomal protein S35, mitochondrial

Alternative UPACC:

Q9Y2Q9; B2RDZ7; Q96Q21

Background:

The Small ribosomal subunit protein bS1m, known alternatively as 28S ribosomal protein S28, mitochondrial or 28S ribosomal protein S35, mitochondrial, plays a crucial role in mitochondrial function. This protein is integral to the mitochondrial ribosome, where it participates in the synthesis of proteins essential for mitochondrial energy production.

Therapeutic significance:

Given its involvement in Combined oxidative phosphorylation deficiency 47, a disorder marked by severe metabolic and developmental challenges, targeting Small ribosomal subunit protein bS1m could offer new avenues for therapeutic intervention. Understanding the role of Small ribosomal subunit protein bS1m could open doors to potential therapeutic strategies.